- Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
- Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
- Invivyd to Participate at the Jefferies Global Healthcare Conference
- Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
- Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
- Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
- Invivyd Elects Two New Independent Members to its Board of Directors
- Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
More ▼
Key statistics
On Wednesday, Invivyd Inc (IVVD:NMQ) closed at 1.10, 4.76% above its 52-week low of 1.05, set on Jul 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.13 |
---|---|
High | 1.14 |
Low | 1.09 |
Bid | 1.10 |
Offer | 1.12 |
Previous close | 1.10 |
Average volume | 1.75m |
---|---|
Shares outstanding | 119.32m |
Free float | 97.61m |
P/E (TTM) | -- |
Market cap | 131.25m USD |
EPS (TTM) | -1.86 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼